MIRA Pharmaceuticals, Inc. (MIRA) Stock Score, Valuation & Financial Research

MIRA Pharmaceuticals, Inc. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MIRA

MIRA Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.71. These figures are a research snapshot, not a buy or sell recommendation.

What MIRA Pharmaceuticals, Inc. does

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

MIRA Pharmaceuticals is a clinical-stage pharmaceutical development company that does not currently generate revenue from product sales. Its business model relies on raising capital to fund the research and development of a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related disorders.

Products and services

  • The company is developing a pipeline of drug candidates including MIRA-55, Ketamir-2, and SKNY-1, which are in preclinical or clinical stages for treating pain, depression, PTSD, and cognitive function.

Brands and product families

  • MIRA-55 — Lead preclinical-stage oral therapeutic candidate for pain and inflammation. Source
  • Ketamir-2 — Clinical-stage drug candidate for neurologic and neuropsychiatric disorders. Source
  • SKNY-1 — Preclinical-stage oral therapeutic candidate targeting CB1/CB2 receptors and MAO-B. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct preclinical and clinical trials. Source

Business strengths to evaluate

  • Exclusive rights to novel drug candidates Ketamir-2 and MIRA-55 in North America Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on successful clinical trials and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MIRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.71
Market capitalization:
29.91M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -9.48M
Free cash flow:
USD -4.66M
Cash:
USD 3.61M
Total debt:
USD 0.00
EPS:
USD -1.38

What stands out

  • Free cash flow is USD -4.66M, negative for the stored period.
  • The balance sheet shows USD 3.61M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.61M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MIRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MIRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MIRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MIRA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MIRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MIRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.